This may be due to the limited infiltration of immune cells into the tumor microenvironment, reduced PD-L1 expression, and lack of antigen presentation, which to some extent diminishes the efficacy of immunotherapy in SCLC (26–28). The gene discussed is CD274; the disease is neoplasm.